Differential SATB1 Expression Reveals Heterogeneity of Cutaneous T-Cell Lymphoma
- PMID: 32771472
- DOI: 10.1016/j.jid.2020.05.120
Differential SATB1 Expression Reveals Heterogeneity of Cutaneous T-Cell Lymphoma
Abstract
SATB1 is an important T-cell specific chromatin organizer in cutaneous T-cell lymphoma, whereas its expression and function in mycosis fungoides (MF) remain ambiguous. Our study aimed to investigate the clinicopathological significance of SATB1 in a cohort of 170 patients with MF. SATB1 expression was heterogeneous among the patients with MF in each clinical stage. High SATB1 expression was associated with epidermal hyperplasia, eosinophil infiltration, less large-cell transformation, and favorable prognosis in MF cases. SATB1 and CD30 coexpression distinguished cutaneous CD30+ lymphoproliferative disorders from MF large-cell transformation. SATB1 silencing in MF lines showed that SATB1 upregulated the genes involved in eosinophil recruitment, including signal transducer and activator of transcription 3 and IL13, and downregulated the genes in cell-cycle progression, which may explain the inferior prognosis for low SATB1-expressing cases. Moreover, SATB1 was inversely correlated with PD-1 expression, indicating an exhausted status of SATB1-negative malignant T cells. SATB1 was positively correlated with toll-like receptors expression, suggesting innate immune activation in high SATB1-expressing MF cases. Therefore, variable SATB1 expression promotes heterogeneity in pathology and clinical outcome of patients with MF.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
SATB1 in Malignant T Cells.J Invest Dermatol. 2018 Aug;138(8):1805-1815. doi: 10.1016/j.jid.2018.03.1526. Epub 2018 May 8. J Invest Dermatol. 2018. PMID: 29751003
-
Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides.Anticancer Res. 2016 Jan;36(1):189-97. Anticancer Res. 2016. PMID: 26722043
-
SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile.J Invest Dermatol. 2018 Aug;138(8):1795-1804. doi: 10.1016/j.jid.2018.02.028. Epub 2018 Mar 3. J Invest Dermatol. 2018. PMID: 29510190
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. J Am Acad Dermatol. 2014. PMID: 24438969 Review.
-
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.Blood. 2000 Apr 1;95(7):2212-8. Blood. 2000. PMID: 10733487 Review.
Cited by
-
Differential molecular programs of cutaneous anaplastic large cell lymphoma and CD30-positive transformed mycosis fungoides.Front Immunol. 2023 Sep 18;14:1270365. doi: 10.3389/fimmu.2023.1270365. eCollection 2023. Front Immunol. 2023. PMID: 37790936 Free PMC article.
-
Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment.JCI Insight. 2023 Feb 22;8(4):e164793. doi: 10.1172/jci.insight.164793. JCI Insight. 2023. PMID: 36649072 Free PMC article. Clinical Trial.
-
High Expression of IKZF2 in Malignant T Cells Promotes Disease Progression in Cutaneous T Cell Lymphoma.Acta Derm Venereol. 2021 Dec 7;101(12):adv00613. doi: 10.2340/actadv.v101.570. Acta Derm Venereol. 2021. PMID: 34853863 Free PMC article.
-
Single nucleotide polymorphism profiles of canine T-cell and null-cell lymphomas.Front Vet Sci. 2024 Aug 7;11:1439706. doi: 10.3389/fvets.2024.1439706. eCollection 2024. Front Vet Sci. 2024. PMID: 39176397 Free PMC article.
-
Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma.Front Oncol. 2021 Jun 24;11:663961. doi: 10.3389/fonc.2021.663961. eCollection 2021. Front Oncol. 2021. PMID: 34249700 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
